Symbols

EXAS(Delisted)

Exact Sciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Revenue Beats Expectation

EPS Beats Expectation

Price Hits 52-week Low

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EXAS

Exact Sciences Corporation

A leading provider of cancer screening and diagnostic tests

Industry

Established Date

02/10/1995

Listing Date

01/30/2001

Exchange

NASDAQ Stock Exchange

Full-time Employees

7,100

Fiscal Year Ends

12-31

Website

www.exactsciences.com

Security Type

Common stock

Office address

5505 Endeavor Lane Madison Wisconsin 53719

Business

Introduction

Exact Sciences Corporation is a molecular diagnostic company focused on the early detection and prevention of colorectal cancer. The company was merged in Delaware on February 10, 1995, and has independent intellectual property rights for non-invasive molecular detection technology, which can detect precancerous lesions of colorectal cancer and colorectal cancer. The company's goal is to become a market leader in patient-friendly diagnostic screening products, producing products for colorectal cancer precancerous lesions and early detection of colorectal cancer. To achieve this goal, the company's strategic route includes the following points: research and development of products, through the clinical approval process of the US Food and Drug Administration (FDA); commercialization of FDA-approved products, detection of colorectal cancer precancerous lesions and colorectal cancer; and substantial product compensation from product payers.

Company Financials

EPS

EXAS has released its 2025 Q4 earnings. EPS was reported at -0.45, versus the expected -0.08, missing expectations. The chart below visualizes how EXAS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

EXAS has released its 2025 Q4 earnings report, with revenue of 878.38M, reflecting a YoY change of 23.12%, and net profit of -85.95M, showing a YoY change of 90.06%. The Sankey diagram below clearly presents EXAS's revenue sources and cost distribution.